| Name | PA452 |
|---|---|
| Synonyms |
PA452, 10 mM in DMSO
2-((3-(Hexyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)(methyl)amino)pyrimidine-5-cboxylic acid PA452,PA-452 5-Pyrimidinecboxylic acid, 2-[[3-(hexyloxy)-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]methylamino] 2-[[3-(Hexyloxy)-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]methylamino]-5-pyrimidinecboxylic acid |
| Description | PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development[1]. |
|---|---|
| Related Catalog | |
| Target |
RXR |
| In Vitro | PA452 inhibits the Troglitazone (TZ)-induced CK13 expression[2]. PA452 (0.01, 0.1, and 1 μM) inhibits RXR in normal human urothelial (NHU) cells[2]. |
| References |
| Molecular Formula | C26H37N3O3 |
|---|---|
| Molecular Weight | 439.59 |